ATE359831T1 - Mikropartikel zur verabreichung von nukleinsaeuren - Google Patents

Mikropartikel zur verabreichung von nukleinsaeuren

Info

Publication number
ATE359831T1
ATE359831T1 AT98904700T AT98904700T ATE359831T1 AT E359831 T1 ATE359831 T1 AT E359831T1 AT 98904700 T AT98904700 T AT 98904700T AT 98904700 T AT98904700 T AT 98904700T AT E359831 T1 ATE359831 T1 AT E359831T1
Authority
AT
Austria
Prior art keywords
microparticles
administration
nucleic acids
nucleic acid
polymeric matrix
Prior art date
Application number
AT98904700T
Other languages
English (en)
Inventor
Mary Lynne Hedley
Joanne M Curley
Robert S Langer
Lynn B Lunsford
Original Assignee
Zycos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/787,547 external-priority patent/US5783567A/en
Application filed by Zycos Inc filed Critical Zycos Inc
Application granted granted Critical
Publication of ATE359831T1 publication Critical patent/ATE359831T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
AT98904700T 1997-01-22 1998-01-22 Mikropartikel zur verabreichung von nukleinsaeuren ATE359831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/787,547 US5783567A (en) 1997-01-22 1997-01-22 Microparticles for delivery of nucleic acid
US325398A 1998-01-06 1998-01-06

Publications (1)

Publication Number Publication Date
ATE359831T1 true ATE359831T1 (de) 2007-05-15

Family

ID=26671537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904700T ATE359831T1 (de) 1997-01-22 1998-01-22 Mikropartikel zur verabreichung von nukleinsaeuren

Country Status (10)

Country Link
EP (2) EP1005374B1 (de)
JP (2) JP2001509178A (de)
AT (1) ATE359831T1 (de)
AU (1) AU724294B2 (de)
CA (1) CA2278450A1 (de)
DE (1) DE69837602T2 (de)
DK (1) DK1005374T3 (de)
ES (1) ES2286845T3 (de)
PT (1) PT1005374E (de)
WO (1) WO1998031398A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
NZ511055A (en) 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
AU2005201927B2 (en) * 1999-03-11 2008-08-21 Eisai Inc. Microparticles for delivery of nucleic acid
CA2276066A1 (en) * 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
EP1173573A1 (de) 1999-04-23 2002-01-23 Pharmexa A/S Verfahren zur herabregulierung von il-5 aktivität
JP2003514832A (ja) * 1999-11-19 2003-04-22 ザイコス インク． 微粒子製造に関する連続フロー法
EP1292285A4 (de) * 2000-06-02 2009-07-22 Eisai Corp North America Darreichungssystem für bioaktive stoffe
AU2001271976A1 (en) * 2000-07-07 2002-01-21 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
WO2002092132A2 (en) * 2001-01-05 2002-11-21 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0602637D0 (en) 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
CA2767063A1 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2013053480A1 (de) * 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Zusammensetzung zur einbringung von nukleinsäuren in zellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
AU6707194A (en) * 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
CA2160877A1 (en) * 1993-04-19 1994-10-27 Michael David Amos Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
AU710504B2 (en) * 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
AU714584B2 (en) * 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
ES2236832T3 (es) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.

Also Published As

Publication number Publication date
AU6250698A (en) 1998-08-07
EP1837017A3 (de) 2009-12-23
DK1005374T3 (da) 2007-08-20
DE69837602T2 (de) 2008-01-17
PT1005374E (pt) 2007-07-18
CA2278450A1 (en) 1998-07-23
EP1005374A4 (de) 2002-08-28
EP1005374B1 (de) 2007-04-18
EP1005374A1 (de) 2000-06-07
ES2286845T3 (es) 2007-12-01
DE69837602D1 (de) 2007-05-31
JP2001509178A (ja) 2001-07-10
JP2009261411A (ja) 2009-11-12
AU724294B2 (en) 2000-09-14
EP1837017A2 (de) 2007-09-26
WO1998031398A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
DE69837602D1 (de) Mikropartikel zur verabreichung von nukleinsaeuren
ATE238434T1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
CY1118963T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
EP1700915A3 (de) Enzymatische DNS-Moleküle
EP0248531A3 (de) Verkapselte Nukleinsäuren
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
DE69534568D1 (de) Säugetier-telomerase
DE69523360D1 (de) Isotherme Amplifikation von Nukleinsäuren durch Strangverdrängung
Kabanov Basic properties of soluble interpolyelectrolyte complexes applied to bioengineering and cell transformations
WO1997025067A3 (en) Polymers
DE59108644D1 (de) Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
FR2650840B1 (fr) Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
BR0010114A (pt) Vetor biologicamente funcional, molécula de dna, molécula de dna codificada para ribozima, método de clonagem de uma transferase g1cnac-a-1.3-fucosil, método de preparação de células hospedeiras recombinantes, células de plantas recombinantes, insetos ou células de insetos recombinantes, molécula de ácido nucléico de peptìdeo (pna), método de produção de plantas ou insetos ou células, método de produção de glicoproteìnas recombinantes, método de produção de glicoproteìnas humanas, recombinantes, método de produção de gligoproteìnas humanas, recombinantes para uso médico, método de seleção de moléculas de dna codificada para uma transferase g1cnac-a-1,-3-fucosil em uma amostra
EP0905254A3 (de) Mit biologisch verträglichen niedermolekularen Polyethyleniminen assoziierte DNA-Vektor
FR2655276B1 (fr) Microemulsions concentrees de matieres organiques diluables sous forme d'emulsions stables et leur procede de preparation.
DE69930515D1 (de) Polyketide, ihre herstellung, und darin benutzte materialien
ATE508736T1 (de) Mikropartikel zur verabreichung von nukleinsäuren
FR2751222B1 (fr) Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique
ATE519859T1 (de) Verfahren zur herstellung von ausgewählten intermolekularen quervernetzungen in nukleinsäuren und ihre verwendungen
WO2000040592A8 (en) Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
KR960704580A (ko) 폴리아미노산 올리고뉴크레오타이드 운반체(polyamino acid oligonucleotide carrier)
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
WO1998030717A3 (en) Vegetal sequences including a polymorphic site and their uses
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
ATE339186T1 (de) Methode zur herstellung von mikropartikeln enthaltend biologisches material

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1005374

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner